Coverage
-
June 02, 2020
Acadia Pharmaceuticals escaped part of the securities fraud claims lodged in a proposed class action over its alleged cover-up of fatality risks associated with its Parkinson's disease treatment, but it must still face the bulk of the suit, a California federal court ruled Monday.
3 other articles on this case.
View all »